SUBSTANTIAL EXTERNAL DOSE RATE VARIABILITY OBSERVED IN A COHORT OF LU-177 PATIENTS INDEPENDENT OF BMI AND SEX-Reference-Cited by-同舟云学术

SUBSTANTIAL EXTERNAL DOSE RATE VARIABILITY OBSERVED IN A COHORT OF LU-177 PATIENTS INDEPENDENT OF BMI AND SEX

Published:2022-09-22 Issue:19 Volume:198 Page:1476-1482
ISSN:0144-8420
Container-title:Radiation Protection Dosimetry
language:en
Short-container-title:

Author:

Bellamy Michael¹^ORCID,Chu Bae¹,Serencsits Brian¹^ORCID,Quinn Brian¹^ORCID,Prasad K¹,Altamirano J¹,Williamson Matthew¹,Miodownik Daniel¹,Abrahams Natalie²,Chen Fanny¹,Bierman David¹,Wutkowski M¹,Dauer Lawrence¹

Affiliation:

1. Department of Medical Physics, Memorial Sloan Kettering , 1275 York Avenue, New York, NY 10065 , USA

2. Siena College , 515 Loudon Road, Loudonville, New York, NY 12211 , USA

Abstract

Abstract External dose rates were measured 1 m away from 230 Lu-177 patients to characterise the variability in normalised dose rates as a function of administered activity, body mass index (BMI) and sex. The largest dose rate observed was 0.07 mSv/h associated with an administered activity of 7.2 GBq. Substantial variability was found in the distribution of the normalised dose rate associated that had an average of 0.0037 mSv/h per GBq and a 95% confidence interval of 0.0024–0.0058 mSv/h per GBq. Based on this study, estimating the patient dose rate based on the Lu-177 gamma exposure factor overestimates the dose rate by a factor of 2. A statistically significant inverse relationship was found between the patient dose rate and patient BMI and an empirically derived equation relating these two quantities was reported. On average, male patient dose rates were 3.5% lower than female dose rates, which may be attributed to the larger average BMI of the male patient group.

Funder

National Institutes of Health

National Cancer Institute Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,General Medicine,Radiation,Radiological and Ultrasound Technology

Link

https://academic.oup.com/rpd/article-pdf/198/19/1476/47069367/ncac187.pdf

Reference27 articles.

1. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy;Hosono;Ann. Nucl. Med.,2018

2. Therapeutic radiopharmaceuticals;Volkert;Chem. Rev.,1999

3. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors;Claringbold;Cancer Biother. Radiopharm.,2012

4. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103;ICRP

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation levels outside a patient undergoing ¹⁷⁷Lu-PSMA radioligand therapy;Journal of Radiological Protection;2024-04-04

2. Monte Carlo simulations for targeted beta therapy: An optimization for liver lesions and comparison of dose distributions in other organs;Radiation Medicine and Protection;2023-12

3. Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry;EJNMMI Physics;2023-11-14

4. Radiation Exposure Assessment of Nuclear Medicine Staff Administering [177Lu]Lu-DOTA-TATE with Active and Passive Dosimetry;2023-07-13

5. Contact restriction time after common nuclear medicine therapies: spreadsheet implementation based on conservative retention function and individual measurements;Journal of Radiological Protection;2023-04-19